CAM
Cormorant Asset Management Portfolio holdings
AUM
$1.34B
This Quarter Return
+56.41%
1 Year Return
+85.27%
3 Year Return
+2,244.39%
5 Year Return
+2,846.94%
10 Year Return
+51,155.97%
AUM
$1.76B
AUM Growth
+$1.76B
(+16%)
Cap. Flow
-$130M
Cap. Flow
% of AUM
-7.41%
Top 10 Holdings %
Top 10 Hldgs %
61.02%
Holding
81
New
8
Increased
13
Reduced
7
Closed
19
Top Buys
| 1 |
MoonLake Immunotherapeutics
MLTX
|
$63.7M |
| 2 |
Zentalis Pharmaceuticals
ZNTL
|
$30.9M |
| 3 |
CBAY
Cymabay Therapeutics
CBAY
|
$27.7M |
| 4 |
EyePoint Pharmaceuticals
EYPT
|
$25.9M |
| 5 |
Vaxcyte
PCVX
|
$19.5M |
Top Sells
| 1 |
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
|
$178M |
| 2 |
Pliant Therapeutics
PLRX
|
$38.4M |
| 3 |
89bio
ETNB
|
$27.5M |
| 4 |
RAIN
Rain Oncology Inc. Common Stock
RAIN
|
$26M |
| 5 |
Monte Rosa Therapeutics
GLUE
|
$22.5M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
Fulcrum Therapeutics
FULC
$353M
| – | – |
-1,081,490
| Closed | -$3.08M |
|
|
ELEV
77
DELISTED
Elevation Oncology
ELEV
| – | – |
-1,952,032
| Closed | -$3.71M |
|
78
Eledon Pharmaceuticals
ELDN
$155M
| – | – |
-1,217,882
| Closed | -$2.87M |
|
79
Cytokinetics
CYTK
$5.98B
| – | – |
-296,000
| Closed | -$10.4M |
|
|
CMMB
80
Chemomab Therapeutics
CMMB
$15.7M
| – | – |
-288,169
| Closed | -$458K |
|
81
Annexon
ANNX
$225M
| – | – |
-1,250,000
| Closed | -$4.81M |
|